结构化运动训练对心力衰竭患者的慢性无能症的影响,其中心脏衰竭患者的喷射分数被保存
Riwa Nasser1, Faro R Verelst1,2, Stephan Mueller3,4
1Department of Cardiology, Antwerp University Hospital (UZA), Edegem, Belgium.
European journal of preventive cardiology
|September 30, 2025
概括
运动训练并没有改善心力衰竭的慢性无能症与保存的喷射分数 (HFpEF). 然而,高强度间歇训练 (HIIT) 和中度持续训练 (MCT) 都改善了HFpEF患者的运动能力.
科学领域:
- 心脏病学 心脏病学
- 运动生理学 运动生理学
- 心脏衰竭研究研究
背景情况:
- 慢性无能症 (CI) 在心力衰竭中普遍存在,具有保存的喷射分数 (HFpEF),影响运动耐受性.
- 在HFpEF患者中,运动训练对CI的影响尚不清楚.
研究的目的:
- 评估不同强度的运动训练对HFpEF患者慢性备的影响.
主要方法:
- 一项涉及HFpEF患者的OptimEx-Clin试验的亚分析,这些患者被随机分配到高强度间歇训练 (HIIT),中度持续训练 (MCT) 或指南对照 (GC) 组.
- 慢性无能症 (CI) 在基线和3个月使用心肺运动测试进行评估,基于药物使用的CI诊断的具体标准.
主要成果:
- 慢性无能 (CI) 在基线时存在于51%的HFpEF患者中,与运动能力和呼吸器效率降低相关.
- 与对照组相比,HIIT和MCT都没有显著改善3个月后的慢性热量指数,预测的峰值心率或CI流行率.
- 与指导方针对照组相比,HIIT和MCT都导致峰值氧气吸收 (V̇O2峰值) 和工作负载显著改善,无论基线CI状态如何.
结论:
- 三个月的HIIT或MCT都没有显著提高老年HFpEF患者的慢性热量储备或降低CI流行率.
- 尽管CI没有改善,但运动训练干预措施 (HIIT和MCT) 有效地改善了这一群体的整体运动能力.
更多相关视频
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
7.0K
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.9K
相关概念视频
01:29Heart Failure II: Pathophysiology
658
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
658
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:17Pathophysiology of Heart Failure
2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
01:22Heart Failure Drugs: β-Blockers
724
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
724
01:26Heart Failure III: Clinical Manifestations
430
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
430
01:22Heart Failure VI: Adjunct Therapies
228
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
228